Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2005-07-01
2009-12-15
Li, Q. Janice (Department: 1633)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S045000, C536S023100
Reexamination Certificate
active
07632822
ABSTRACT:
The invention relates to the therapeutic use of oligonucleotides as immunostimulatory agents in immunotherapy applications. More particularly, the invention provides immunomers and an immunostimulatory oligonucleotides for use in methods for generating an immune response or for treating a patient in need of immunostimulation. The immunomers and an immunostimulatory oligonucleotides of the invention preferably comprise novel purines. The immunomers according to the invention further comprise at least two oligonucleotides linked at their 3′ ends, internucleoside linkages or functionalized nucleobase or sugar to a non-nucleotidic linker, at least one of the oligonucleotides being an immunomodulatory oligonucleotide and having an accessible 5′ end.
REFERENCES:
patent: 5149798 (1992-09-01), Agrawal et al.
patent: 5366878 (1994-11-01), Pederson et al.
patent: 5594121 (1997-01-01), Froehler et al.
patent: 5635377 (1997-06-01), Pederson et al.
patent: 5652355 (1997-07-01), Metelev et al.
patent: 5912332 (1999-06-01), Agrawal et al.
patent: 6143881 (2000-11-01), Metelev et al.
patent: 6346614 (2002-02-01), Metelev et al.
patent: 2004/0097719 (2004-05-01), Agrawal et al.
patent: 2004/0156825 (2004-08-01), Agrawal et al.
patent: 2004/0266709 (2004-12-01), Kandimalla et al.
patent: 2004/0266710 (2004-12-01), Kandimalla et al.
patent: 2005/0026861 (2005-02-01), Kandimalla et al.
patent: 2006/0014713 (2006-01-01), Agrawal et al.
patent: 2006/0019909 (2006-01-01), Agrawal et al.
patent: 2006/0094680 (2006-05-01), Agrawal et al.
patent: 2006/0094681 (2006-05-01), Agrawal et al.
patent: 2006/0142224 (2006-06-01), Kandimalla et al.
patent: WO 98/49288 (1998-11-01), None
patent: WO 01/12804 (2001-02-01), None
patent: PCT/US01/13682 (2001-04-01), None
patent: WO 01/55370 (2001-08-01), None
patent: PCT/US01/30137 (2001-09-01), None
patent: WO 02/26757 (2002-04-01), None
Kandimalla et al, Bioconjugate Chem. 13, 966-974, 2002.
Kandimalla et al, Nucleic Acid Research vol. 31, No. 9, 2003.
Kandimalla et al, PNAS 100(24): 14303-14308, 2003.
Donnelly et al, Nature Medicine, 9(11):1354-1356, 2003.
DeGruijI et al, Nature Medicine, 5110: 1124-1125, 1999.
Bitton R. J., Current Opinion in Molecular Therapeutics 611: 17-26, 2004; Abstract only.
Weiner, J. Leukoc. Biol. 68: 455-463, 2000.
Krieg et al, Pharmacol. & Therap. 84: 113-120,1999.
Ballas et al, J. Immunol. 167: 4878-4886, 2001.
Agrawal et al, Trends in Molecular Medicine 8(3): 114-121, 2002.
Wooldridge et al, Blood 89(8):2994-2998, 1997.
Baral et al, Cancer Immunol. Immunother. 52(3):317-327, 2003.
van Ojik et al, Cancer Research 63(17):5595-5600, 2003.
Yu et al, J. Med. Chem. 45:4540-4548, 2002.
Souza et al, Clin. and Diag. Lab. Immunol. 7(2): 175-181, 2000.
Agrawal et al, Curr. Cancer Drug Targets 1: 197-209, 2001.
Decker et al, Blood 99(4): 1320-1326, 2002.
Kandimalla et al, PNAS 102(19):6925-6930, 2005.
Agrawal et al., Meth. in Mol. Biol., “Protocols for Oligonucleotides and Analogs”, 20:165-189, 1993.
Oligonucleotides and Analogues, A Practical approach, 87-108 (F. Eckstein, ed., 1991).
Khorana et al., J. Mol. Bio., 72:209 (1972).
Beaucage et al., Tetrahedron lett., 22:1859-1862 (1981).
Agrawal et al., Tetrahedron lett., 28:3539-3542 (1987).
Connolly et al., Biochem., 23:3443 (1984).
Jager et al., Biochem., 27:7237 (1988).
Agrawal et al., Proc. Natl. Acad. Sci. (USA), 85:7079-7082 (1988).
Kuramoto et al., Jpn. J. Cancer Res., 83:1128-1131 (1992).
Krieg et al., nature, 371:546-549 (1995).
Liang et al., J. Clin. Invest., 98:1119-1129 (1996).
Moldoveanu et al., Vaccine, 16:1216-124 (1998).
McCluskie et al., J. Immunol., 161:4463-4466(1998).
Hartman et al., J. Immunol., 164:1617-1624 (2000).
Zhao et al., Biocehm. Pharmacol., 51:173-182 (1996).
Zhao et al., Biochem. Pharmacol., 52:1537-1544 (1996).
Zhao et al., Antisense Nucleic Acid Drug Dev., 7:495-502 (1997).
Zhao et al., Bioorg. Med. Chem. Lett., 9:3453-3458 (1999).
Zhao et al., Bioorg. Med. Chem. Lett., 10:1051-1054 (2000).
Yu et al., Bioorg. Med. Chem. Lett., 10:2585-2588 (2000).
Yu et al., Bioorg. Med. Chem. Lett., 11:2263-2267 (2001).
Kandimalla et al., Bioorg. Med. Chem., 9:807-813 (2001).
Noronha et al., Biocehm., 39:7050-7062 (2000).
Yu et al., “Immunomers'—Novel 3′-3′-Linked CpG Oligodeoxyribonucleotides as Potent Immunomodulatory Agents”, Nucleic Acids Res., 30(20):4460-4469 (2002).
Bhagat et al., “CpG Penta- and Hexadeoxyribonucleotides as Potent Immunomodulatory Agents”, Biochem. Biophys. Res. Comm., 300(4):853-861 (2003).
Yu et al., “Requirement of Nucleobase Proximal to CpG Dinucleotide for Immunostimulatory Activity of Synthetic CpD DNA”, Bioorg. & Med. Chem., 11(3):459-464 (2003).
Agrawal Sudhir
Bhagat Lakshmi
Kandimalla Ekambar
Yu Dong
Hill Kevin K.
Idera Pharmaceuticals Inc.
Keown Wayne
Keown & Zucchero, LLP
Li Q. Janice
LandOfFree
Modulation of immunostimulatory properties of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Modulation of immunostimulatory properties of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Modulation of immunostimulatory properties of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4075778